Abcellera Biologics Inc (ABCL) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 1.13, the current P/B ratio is approximately -5.78% higher. Relative to its 5-year average P/B ratio of 2.34, the current P/B ratio is about -54.52% higher. Abcellera Biologics Inc (ABCL) has a Forward Free Cash Flow (FCF) yield of approximately -14.91%. Compared to its 3-year average FCF yield of -12.48%, the current FCF yield is approximately 19.45% lower. Relative to its 5-year average FCF yield of -4.96%, the current FCF yield is about 200.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ABCL competitors is 20.00, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL.O) exhibits a P/S ratio of 18.51, which is -7.43% above the industry average. Given its robust revenue growth of 788.18%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ABCL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ABCL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ABCL currently overvalued or undervalued?

What is Abcellera Biologics Inc (ABCL) fair value?

ABCL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Abcellera Biologics Inc (ABCL) is between 2.90 to 8.10 according to relative valuation method.

How does ABCL's valuation metrics compare to the industry average?

The average P/S ratio for ABCL's competitors is 20.00, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL) exhibits a P/S ratio of 18.51, which is -7.43% above the industry average. Given its robust revenue growth of 788.18%, this premium appears sustainable.

What is the current P/B ratio for Abcellera Biologics Inc (ABCL) as of Mar 02 2026?

As of Mar 02 2026, Abcellera Biologics Inc (ABCL) has a P/B ratio of 1.06. This indicates that the market values ABCL at 1.06 times its book value.

What is the current FCF Yield for Abcellera Biologics Inc (ABCL) as of Mar 02 2026?

As of Mar 02 2026, Abcellera Biologics Inc (ABCL) has a FCF Yield of -14.91%. This means that for every dollar of Abcellera Biologics Inc's market capitalization, the company generates -14.91 cents in free cash flow.

What is the current Forward P/E ratio for Abcellera Biologics Inc (ABCL) as of Mar 02 2026?

As of Mar 02 2026, Abcellera Biologics Inc (ABCL) has a Forward P/E ratio of -4.76. This means the market is willing to pay $-4.76 for every dollar of Abcellera Biologics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Abcellera Biologics Inc (ABCL) as of Mar 02 2026?

As of Mar 02 2026, Abcellera Biologics Inc (ABCL) has a Forward P/S ratio of 18.51. This means the market is valuing ABCL at $18.51 for every dollar of expected revenue over the next 12 months.

ABCL Valuation